Multiple myeloma : risk factors, diagnosis, and treatments /

Multiple myeloma (MM) is a hematological malignancy characterized by the clonal expansion of monoclonal immunoglobulin-secreting plasma cells in the bone marrow (BM). MM is associated with lytic bone lesions, anemia, immunodeficiency, and renal impairment. Multiple myeloma accounts for more than 10%...

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Otros Autores: Holt, Steve (Editor )
Formato: Electrónico eBook
Idioma:Inglés
Publicado: New York : Nova Biomedical, [2014]
Colección:Cancer etiology, diagnosis, and treatments.
Temas:
Multiple myeloma.
Multiple Myeloma
Myélome multiple.
HEALTH & FITNESS > Diseases > General.
MEDICAL > Clinical Medicine.
MEDICAL > Diseases.
MEDICAL > Evidence-Based Medicine.
MEDICAL > Internal Medicine.
Acceso en línea:Texto completo
Tabla de Contenidos:
  • MULTIPLE MYELOMA: RISK FACTORS, DIAGNOSIS AND TREATMENTS
  • MULTIPLE MYELOMA: RISK FACTORS, DIAGNOSIS AND TREATMENTS
  • Library of Congress Cataloging-in-Publication Data
  • Contents
  • Preface
  • Chapter 1: Recent Advances in Diagnosis and Treatment of Multiple Myeloma
  • Abstract
  • Introduction
  • Current Therapies for Newly Diagnosed MM
  • Novel Targeted Therapies for MM
  • Conclusion
  • Acknowledgment
  • References
  • Chapter 2: Development of Proteasome Inhibitors for the Treatment of Multiple Myeloma
  • Abstract
  • Introduction
  • Ubiquitin-Dependent ProteolysisProteasome Inhibitors
  • Bortezomib
  • Bortezomib in Preclinical Studies on Human Myeloma Cell Lines and Primary Patient Multiple Myeloma Cells
  • Bortezomib in Relapsed and/or Refractory Multiple Myeloma
  • Clinical Studies
  • The Second-Generation Proteasome Inhibitors with More Potency and Fewer Side-Effects Studied in Multiple Myeloma
  • Conclusion and Perspectives
  • Acknowledgments
  • References
  • Chapter 3: Cereblon as the Cellular Target Responsible for the Anti-Multiple Myeloma Activity of Immunomodulatory Drugs (Thalidomide, Lenalidomide and Pomalidomide)Abstract
  • Introduction
  • Cereblon and Its Role in Memory and Learning
  • Cereblon as a Negative Modulator of the Adenosine Monophosphate-Activated Protein Kinase (AMPK)
  • Immunomodulatory Drugs
  • Mechanism of Immunomodulatory Drugs Action in the Treatment of Multiple Myeloma
  • Immunomodulatory Activities of IMiDs
  • Anti-Angiogenic Properties of IMiDs
  • Inhibition of Cell Cycle and Induction of Apoptosis by IMiDsDisruption of Bone Marrow Stromal Support for Malignant MM Cells
  • Effect of IMiDs on Myeloma Cell Proliferation
  • Cereblon as the Direct Target Protein of IMiDs
  • Cereblon as a Primary Target for Thalidomide Teratogenicity
  • The Role of Ikaros Family Proteins in IMiDs and CRBN Mechanism
  • Measurement of Cereblon mRNA and Cereblon Protein Levels as Biomarkers for IMiDs Response
  • Conclusion and Perspectives
  • Acknowledgments
  • References
  • Chapter 4: Review of Risk Factors, Diagnosis Criteria and Treatment in Multiple MyelomaAbstract
  • Introduction
  • Risk Factors
  • Diagnosis
  • Treatment
  • When Should Treatment Be Started?
  • Choice Initial Drug Therapy
  • Transplantation
  • Consolidation and Maintenance Therapy After Transplantation
  • Treatment Options for Unfit Patient
  • References
  • Chapter 5: Diagnosis and Management of Oral Manifestations of Multiple Myeloma
  • Abstract
  • 1. Incidence and Case Series
  • 2. Clinical Diagnosis
  • 3. Diagnostic Imaging

Ejemplares similares